The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons
The lack of early diagnostic biomarkers for schizophrenia greatly limits treatment options that deliver therapeutic agents to affected cells at a timely manner. While previous schizophrenia biomarker research has identified various biological signals that are correlated with certain diseases, their...
Gespeichert in:
| Veröffentlicht in: | Frontiers in molecular neuroscience 2021-11, Vol.14, p.756613-756613, Article 756613 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 756613 |
|---|---|
| container_issue | |
| container_start_page | 756613 |
| container_title | Frontiers in molecular neuroscience |
| container_volume | 14 |
| creator | Lee, Davin Seo, Jinsoo Jeong, Hae Chan Lee, Hyosang Lee, Sung Bae |
| description | The lack of early diagnostic biomarkers for schizophrenia greatly limits treatment options that deliver therapeutic agents to affected cells at a timely manner. While previous schizophrenia biomarker research has identified various biological signals that are correlated with certain diseases, their reliability and practicality as an early diagnostic tool remains unclear. In this article, we discuss the use of atypical epigenetic and/or consequent transcriptional alterations (ETAs) as biomarkers of early-stage schizophrenia. Furthermore, we review the viability of discovering and applying these biomarkers through the use of cutting-edge technologies such as human induced pluripotent stem cell (iPSC)-derived neurons, brain models, and single-cell level analyses. |
| doi_str_mv | 10.3389/fnmol.2021.756613 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2596806476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8f0e77b326464418bbc9c9772a40590e</doaj_id><sourcerecordid>2596806476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-5fefc0de290661c0f2600662cb5ee2be5d8486843e3352c97c4026472f6021293</originalsourceid><addsrcrecordid>eNqNUk1v1DAQjRCIlsIP4BaJCxLK4o_YTi5IdLeFShVU6nK2HGey8ZK1t3ZSVI795czuVhXlxMkj-70388Yvy95SMuO8qj92fhOGGSOMzpSQkvJn2TGVkhWC1PXzv-qj7FVKa0Ikk4K_zI54WUlFK3mc3S97yK8gpi3Y0d1CykOXn5k43OULZ1Y-JLe_ura9-x22fQTvTL7sY5hWfT4ieQHjjhr8nrl1K_Bh42wqTk2CNj91YWPiT-yQO5-7q-t5sYCIndr8G0wx-PQ6e9GZIcGbh_Mk-3F-tpx_LS6_f7mYf74sbKnIWIgOOktaYDVBq5Z0TKIhyWwjAFgDoq3QVVVy4FwwWytbEiZLxTqJC2I1P8kuDrptMGu9jQ7nutPBOL2_CHGlTRydHUBXHQGlGo58WZa0ahpbo6JipiSiJoBanw5a26nZQGvBj9EMT0SfvnjX61W41ZXEn1McBd4_CMRwM0Ea9cYlC8NgPIQpaTSnOFFCCYS--we6DlP0uCrNRC0rgiYlougBZWNIKUL3OAwlepcWvU-L3qVFH9KCnA8Hzi9oQpesA2_hkUcIUUxSKjhWhCK6-n_03I1mF4p5mPzI_wCTH9L9</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2596806476</pqid></control><display><type>article</type><title>The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lee, Davin ; Seo, Jinsoo ; Jeong, Hae Chan ; Lee, Hyosang ; Lee, Sung Bae</creator><creatorcontrib>Lee, Davin ; Seo, Jinsoo ; Jeong, Hae Chan ; Lee, Hyosang ; Lee, Sung Bae</creatorcontrib><description>The lack of early diagnostic biomarkers for schizophrenia greatly limits treatment options that deliver therapeutic agents to affected cells at a timely manner. While previous schizophrenia biomarker research has identified various biological signals that are correlated with certain diseases, their reliability and practicality as an early diagnostic tool remains unclear. In this article, we discuss the use of atypical epigenetic and/or consequent transcriptional alterations (ETAs) as biomarkers of early-stage schizophrenia. Furthermore, we review the viability of discovering and applying these biomarkers through the use of cutting-edge technologies such as human induced pluripotent stem cell (iPSC)-derived neurons, brain models, and single-cell level analyses.</description><identifier>ISSN: 1662-5099</identifier><identifier>EISSN: 1662-5099</identifier><identifier>DOI: 10.3389/fnmol.2021.756613</identifier><identifier>PMID: 34867186</identifier><language>eng</language><publisher>LAUSANNE: Frontiers Media Sa</publisher><subject>Biomarkers ; Brain research ; Cell culture ; Clinical outcomes ; Disease ; Dopamine ; epigenetic alteration ; Epigenetics ; Health risk assessment ; Hyperactivity ; iPSC ; Life Sciences & Biomedicine ; Mental disorders ; Molecular Neuroscience ; Neurosciences ; Neurosciences & Neurology ; organoid ; Patients ; Physiology ; Psychosis ; Risk factors ; Schizophrenia ; Science & Technology ; Transcription ; transcriptional alteration</subject><ispartof>Frontiers in molecular neuroscience, 2021-11, Vol.14, p.756613-756613, Article 756613</ispartof><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Lee, Seo, Jeong, Lee and Lee. 2021 Lee, Seo, Jeong, Lee and Lee</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000726115300001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c470t-5fefc0de290661c0f2600662cb5ee2be5d8486843e3352c97c4026472f6021293</citedby><cites>FETCH-LOGICAL-c470t-5fefc0de290661c0f2600662cb5ee2be5d8486843e3352c97c4026472f6021293</cites><orcidid>0000-0001-6432-6964</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633873/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633873/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,27928,27929,53795,53797</link.rule.ids></links><search><creatorcontrib>Lee, Davin</creatorcontrib><creatorcontrib>Seo, Jinsoo</creatorcontrib><creatorcontrib>Jeong, Hae Chan</creatorcontrib><creatorcontrib>Lee, Hyosang</creatorcontrib><creatorcontrib>Lee, Sung Bae</creatorcontrib><title>The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons</title><title>Frontiers in molecular neuroscience</title><addtitle>FRONT MOL NEUROSCI</addtitle><description>The lack of early diagnostic biomarkers for schizophrenia greatly limits treatment options that deliver therapeutic agents to affected cells at a timely manner. While previous schizophrenia biomarker research has identified various biological signals that are correlated with certain diseases, their reliability and practicality as an early diagnostic tool remains unclear. In this article, we discuss the use of atypical epigenetic and/or consequent transcriptional alterations (ETAs) as biomarkers of early-stage schizophrenia. Furthermore, we review the viability of discovering and applying these biomarkers through the use of cutting-edge technologies such as human induced pluripotent stem cell (iPSC)-derived neurons, brain models, and single-cell level analyses.</description><subject>Biomarkers</subject><subject>Brain research</subject><subject>Cell culture</subject><subject>Clinical outcomes</subject><subject>Disease</subject><subject>Dopamine</subject><subject>epigenetic alteration</subject><subject>Epigenetics</subject><subject>Health risk assessment</subject><subject>Hyperactivity</subject><subject>iPSC</subject><subject>Life Sciences & Biomedicine</subject><subject>Mental disorders</subject><subject>Molecular Neuroscience</subject><subject>Neurosciences</subject><subject>Neurosciences & Neurology</subject><subject>organoid</subject><subject>Patients</subject><subject>Physiology</subject><subject>Psychosis</subject><subject>Risk factors</subject><subject>Schizophrenia</subject><subject>Science & Technology</subject><subject>Transcription</subject><subject>transcriptional alteration</subject><issn>1662-5099</issn><issn>1662-5099</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>GIZIO</sourceid><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNUk1v1DAQjRCIlsIP4BaJCxLK4o_YTi5IdLeFShVU6nK2HGey8ZK1t3ZSVI795czuVhXlxMkj-70388Yvy95SMuO8qj92fhOGGSOMzpSQkvJn2TGVkhWC1PXzv-qj7FVKa0Ikk4K_zI54WUlFK3mc3S97yK8gpi3Y0d1CykOXn5k43OULZ1Y-JLe_ura9-x22fQTvTL7sY5hWfT4ieQHjjhr8nrl1K_Bh42wqTk2CNj91YWPiT-yQO5-7q-t5sYCIndr8G0wx-PQ6e9GZIcGbh_Mk-3F-tpx_LS6_f7mYf74sbKnIWIgOOktaYDVBq5Z0TKIhyWwjAFgDoq3QVVVy4FwwWytbEiZLxTqJC2I1P8kuDrptMGu9jQ7nutPBOL2_CHGlTRydHUBXHQGlGo58WZa0ahpbo6JipiSiJoBanw5a26nZQGvBj9EMT0SfvnjX61W41ZXEn1McBd4_CMRwM0Ea9cYlC8NgPIQpaTSnOFFCCYS--we6DlP0uCrNRC0rgiYlougBZWNIKUL3OAwlepcWvU-L3qVFH9KCnA8Hzi9oQpesA2_hkUcIUUxSKjhWhCK6-n_03I1mF4p5mPzI_wCTH9L9</recordid><startdate>20211112</startdate><enddate>20211112</enddate><creator>Lee, Davin</creator><creator>Seo, Jinsoo</creator><creator>Jeong, Hae Chan</creator><creator>Lee, Hyosang</creator><creator>Lee, Sung Bae</creator><general>Frontiers Media Sa</general><general>Frontiers Research Foundation</general><general>Frontiers Media S.A</general><scope>17B</scope><scope>BLEPL</scope><scope>DTL</scope><scope>DVR</scope><scope>EGQ</scope><scope>GIZIO</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6432-6964</orcidid></search><sort><creationdate>20211112</creationdate><title>The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons</title><author>Lee, Davin ; Seo, Jinsoo ; Jeong, Hae Chan ; Lee, Hyosang ; Lee, Sung Bae</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-5fefc0de290661c0f2600662cb5ee2be5d8486843e3352c97c4026472f6021293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Brain research</topic><topic>Cell culture</topic><topic>Clinical outcomes</topic><topic>Disease</topic><topic>Dopamine</topic><topic>epigenetic alteration</topic><topic>Epigenetics</topic><topic>Health risk assessment</topic><topic>Hyperactivity</topic><topic>iPSC</topic><topic>Life Sciences & Biomedicine</topic><topic>Mental disorders</topic><topic>Molecular Neuroscience</topic><topic>Neurosciences</topic><topic>Neurosciences & Neurology</topic><topic>organoid</topic><topic>Patients</topic><topic>Physiology</topic><topic>Psychosis</topic><topic>Risk factors</topic><topic>Schizophrenia</topic><topic>Science & Technology</topic><topic>Transcription</topic><topic>transcriptional alteration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Davin</creatorcontrib><creatorcontrib>Seo, Jinsoo</creatorcontrib><creatorcontrib>Jeong, Hae Chan</creatorcontrib><creatorcontrib>Lee, Hyosang</creatorcontrib><creatorcontrib>Lee, Sung Bae</creatorcontrib><collection>Web of Knowledge</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Social Sciences Citation Index</collection><collection>Web of Science Primary (SCIE, SSCI & AHCI)</collection><collection>Web of Science - Social Sciences Citation Index – 2021</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in molecular neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Davin</au><au>Seo, Jinsoo</au><au>Jeong, Hae Chan</au><au>Lee, Hyosang</au><au>Lee, Sung Bae</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons</atitle><jtitle>Frontiers in molecular neuroscience</jtitle><stitle>FRONT MOL NEUROSCI</stitle><date>2021-11-12</date><risdate>2021</risdate><volume>14</volume><spage>756613</spage><epage>756613</epage><pages>756613-756613</pages><artnum>756613</artnum><issn>1662-5099</issn><eissn>1662-5099</eissn><abstract>The lack of early diagnostic biomarkers for schizophrenia greatly limits treatment options that deliver therapeutic agents to affected cells at a timely manner. While previous schizophrenia biomarker research has identified various biological signals that are correlated with certain diseases, their reliability and practicality as an early diagnostic tool remains unclear. In this article, we discuss the use of atypical epigenetic and/or consequent transcriptional alterations (ETAs) as biomarkers of early-stage schizophrenia. Furthermore, we review the viability of discovering and applying these biomarkers through the use of cutting-edge technologies such as human induced pluripotent stem cell (iPSC)-derived neurons, brain models, and single-cell level analyses.</abstract><cop>LAUSANNE</cop><pub>Frontiers Media Sa</pub><pmid>34867186</pmid><doi>10.3389/fnmol.2021.756613</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-6432-6964</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-5099 |
| ispartof | Frontiers in molecular neuroscience, 2021-11, Vol.14, p.756613-756613, Article 756613 |
| issn | 1662-5099 1662-5099 |
| language | eng |
| recordid | cdi_proquest_journals_2596806476 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Brain research Cell culture Clinical outcomes Disease Dopamine epigenetic alteration Epigenetics Health risk assessment Hyperactivity iPSC Life Sciences & Biomedicine Mental disorders Molecular Neuroscience Neurosciences Neurosciences & Neurology organoid Patients Physiology Psychosis Risk factors Schizophrenia Science & Technology Transcription transcriptional alteration |
| title | The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T07%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Perspectives%20of%20Early%20Diagnosis%20of%20Schizophrenia%20Through%20the%20Detection%20of%20Epigenomics-Based%20Biomarkers%20in%20iPSC-Derived%20Neurons&rft.jtitle=Frontiers%20in%20molecular%20neuroscience&rft.au=Lee,%20Davin&rft.date=2021-11-12&rft.volume=14&rft.spage=756613&rft.epage=756613&rft.pages=756613-756613&rft.artnum=756613&rft.issn=1662-5099&rft.eissn=1662-5099&rft_id=info:doi/10.3389/fnmol.2021.756613&rft_dat=%3Cproquest_pubme%3E2596806476%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2596806476&rft_id=info:pmid/34867186&rft_doaj_id=oai_doaj_org_article_8f0e77b326464418bbc9c9772a40590e&rfr_iscdi=true |